OSURORASURE TECHNOLOGIES INC
Surgical & Medical Instruments & Apparatus
- Revenue
- $115M
- 38% YoY
- Operating margin
- -62.6%
- 312% YoY
- EBITDA
- −$62M
- 255% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear9% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-31% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear12% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $234M | $387M | $405M | $186M | $115M | 38% |
| Operating income | −$10M | −$22M | $33M | −$28M | −$72M | 155% |
| Net income | −$23M | −$17M | $54M | −$20M | −$69M | 252% |
| Operating cash flow | −$35M | −$47M | $142M | $27M | −$49M | 279% |
| Capex | $22M | $7M | $6M | $4M | $4M | 11% |
| Stock-based comp | $8M | $12M | $11M | $12M | $10M | 15% |
| Buybacks | $2M | $2M | $0 | $0 | $15M |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 23 | 81 |
| FY2024 | — | — | 45 | 85 |
| FY2023 | — | — | 102 | 106 |
| FY2022 | — | — | 60 | 99 |
| FY2021 | — | — | 108 | 125 |